Collegium Pharmaceutical Inc

-0.42 (-1.85%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)785.32M
Current PE18.71
Forward PE 5.74
2yr Forward PE 5.04
See more stats
Estimates Current Quarter
Revenue$84.42 Million
Adjusted EPS$0.95
See more estimates
10-Day MA$22.80
50-Day MA$22.95
200-Day MA$21.69
See more pivots

Collegium Pharmaceutical Inc Stock, NASDAQ:COLL

100 Technology Center Drive, Suite 300, Stoughton, Massachusetts 02072
United States of America
Phone: +1.781.713.3699
Number of Employees: 234


Collegium Pharmaceutical, Inc. operates as a pharmaceutical company. The firm engages in the development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR. The Xtampza ER provides pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. The Nucynta ER for the treatment of chronic pain and neuropathic pain associated with diabetic peripheral neuropathy. The Nucynta IR is a release formulation of tapentadol indicated for the management of acute pain severe enough to require an opioid analgesic. The company was founded by Michael Thomas Heffernan in October 2003 and is headquartered in Stoughton, MA.